UY33400A - Vectores de parapoxvirus - Google Patents

Vectores de parapoxvirus

Info

Publication number
UY33400A
UY33400A UY0001033400A UY33400A UY33400A UY 33400 A UY33400 A UY 33400A UY 0001033400 A UY0001033400 A UY 0001033400A UY 33400 A UY33400 A UY 33400A UY 33400 A UY33400 A UY 33400A
Authority
UY
Uruguay
Prior art keywords
parapoxvirus
recombinant
vectors
parapoxvirus vectors
genomes
Prior art date
Application number
UY0001033400A
Other languages
English (en)
Inventor
Martinon Olivier Michel
Nanda Kumar Damavarapu Reddy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY33400A publication Critical patent/UY33400A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a parapoxvirus recombinantes portadores en sus genomas que comprenden ADN heterólogo derivado de un virus de la rabia, a la preparación de dichos constructos y a su uso en composiciones inmunogénicas y vacunas . Adem ás se refiere al uso de parapoxvirus recombinantes para diagnóstico .
UY0001033400A 2010-05-21 2011-05-23 Vectores de parapoxvirus UY33400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34698810P 2010-05-21 2010-05-21
US41428710P 2010-11-16 2010-11-16

Publications (1)

Publication Number Publication Date
UY33400A true UY33400A (es) 2011-12-30

Family

ID=44972661

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033400A UY33400A (es) 2010-05-21 2011-05-23 Vectores de parapoxvirus

Country Status (17)

Country Link
US (1) US20110287051A1 (es)
EP (1) EP2571521A1 (es)
JP (1) JP5890399B2 (es)
KR (2) KR20130008645A (es)
CN (1) CN103260644A (es)
AR (1) AR081409A1 (es)
AU (1) AU2011254315B2 (es)
BR (1) BR112012029633A8 (es)
CA (1) CA2798055C (es)
CL (1) CL2012003219A1 (es)
CO (1) CO6670515A2 (es)
MX (1) MX338052B (es)
NZ (1) NZ603431A (es)
RU (1) RU2545694C2 (es)
UY (1) UY33400A (es)
WO (1) WO2011145013A1 (es)
ZA (1) ZA201208264B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014116334A1 (de) * 2014-11-10 2016-05-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Herstellung von rekombinanten Expressionsvektoren
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
BR112018069371A2 (pt) * 2016-03-21 2019-01-22 South Dakota Board Of Regents construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno
CN111944769B (zh) * 2020-08-10 2022-06-28 塔里木大学 一种狂犬病毒g蛋白-羊痘病毒重组疫苗的构建方法
WO2022033573A1 (zh) * 2020-08-13 2022-02-17 苏州般若生物科技有限公司 一种突变型羊传染性脓疱皮炎病毒及其用途
CN117298263A (zh) * 2023-09-27 2023-12-29 成都迈科康生物科技有限公司 一种重组狂犬病疫苗及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
CA2247336C (en) * 1996-02-28 2008-06-17 Bayer Aktiengesellschaft Parapoxviruses containing foreign dna, their production and their use in vaccines
EP1499355A4 (en) * 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
JP4439263B2 (ja) 2001-12-10 2010-03-24 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルス含有調合物およびその調製方法
JP5588990B2 (ja) * 2008-10-31 2014-09-10 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種

Also Published As

Publication number Publication date
WO2011145013A1 (en) 2011-11-24
RU2545694C2 (ru) 2015-04-10
AU2011254315B2 (en) 2015-05-14
MX2012013451A (es) 2013-01-22
ZA201208264B (en) 2014-01-29
BR112012029633A2 (pt) 2016-09-20
CA2798055A1 (en) 2011-11-24
AU2011254315A1 (en) 2013-01-10
KR20150015551A (ko) 2015-02-10
NZ603431A (en) 2014-06-27
US20110287051A1 (en) 2011-11-24
BR112012029633A8 (pt) 2017-12-05
EP2571521A1 (en) 2013-03-27
JP5890399B2 (ja) 2016-03-22
AR081409A1 (es) 2012-08-29
JP2013535953A (ja) 2013-09-19
CA2798055C (en) 2015-11-24
CN103260644A (zh) 2013-08-21
KR20130008645A (ko) 2013-01-22
MX338052B (es) 2016-03-31
CO6670515A2 (es) 2013-05-15
CL2012003219A1 (es) 2013-04-05
RU2012149036A (ru) 2014-06-27

Similar Documents

Publication Publication Date Title
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
CO6670515A2 (es) Vectores de parapoxvirus
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
MY159543A (en) Recombinant avian influenza vaccine and uses thereof
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
UY33523A (es) ?vectores de parapoxvirus?.
WO2015052543A3 (en) Malaria vaccination
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
PT2658570T (pt) Composições e métodos vacinais contra o vírus da diarreia viral bovina tipo 1b
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
ZA201503036B (en) Chimeric vaccine antigens against hepatitis c virus
WO2014008475A3 (en) Compositions and methods related to viral vaccines
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same
WO2014015287A3 (en) Influenza vaccine consisting of a mva which expresses influenza antigens fused to vaccinia secretory signal sequences
EP2501405A4 (en) COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS
TR201907091T4 (tr) Yeni adjuvan kompozisyonları.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200629